Scholarlink

Background <p>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are associated with immune-related adverse events, including cardiac immune-related adverse events (cardiac irAEs). Early identification of patients at risk for cardiac irAEs is crucial, and echocardiographic parameters may serve as valuable predictors. This study aimed to evaluate the predictive utility of echocardiographic indices in assessing cardiac irAE risk in Japanese patients receiving ICI therapy.</p> Methods <p>This retrospective study analyzed patients treated with ICIs at the University of Fukui Hospital between November 2015 and October 2018. Cardiac irAEs were defined according to the ESC guidelines.</p> Results <p>Among 73 patients, six (8%) developed cardiac irAEs, with no fatalities. Echocardiographic assessment before ICI initiation revealed that patients who later developed cardiac irAEs had significantly lower ejection fractions (EFs) (<i>p</i> &lt; 0.05). Receiver operating characteristic analysis demonstrated that left ventricular end-systolic diameters (LVDs) (area under the curve: AUC = 0.660) and EFs (AUC = 0.797) had moderate predictive value for cardiac irAEs. Kaplan–Meier analysis showed a higher probability of cardiac irAEs in patients with LVDs and EFs beyond specific thresholds (<i>p</i> &lt; 0.01). Poisson regression analysis indicated a decreasing risk of cardiac irAEs over time after ICI initiation.</p> Conclusion <p>Baseline echocardiographic parameters, particularly LVDs and EFs, can be useful predictors of cardiac irAEs in patients receiving ICI therapy. Early echocardiographic evaluation may facilitate risk stratification and improve monitoring strategies for cardiac irAEs<Emphasis Type="BoldItalic">.</Emphasis></p> Clinical trial registration number <p>UMIN000023840.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Utility of echocardiographic parameters in predicting cardiac immune-related adverse events in Japanese patients undergoing immune checkpoint inhibitor therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Junya Yamaguchi,
  • Tetsuji Morishita,
  • Hiroyasu Uzui,
  • Kanae Hasegawa,
  • Hiroyuki Ikeda,
  • Hiroshi Tada

摘要

Background

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are associated with immune-related adverse events, including cardiac immune-related adverse events (cardiac irAEs). Early identification of patients at risk for cardiac irAEs is crucial, and echocardiographic parameters may serve as valuable predictors. This study aimed to evaluate the predictive utility of echocardiographic indices in assessing cardiac irAE risk in Japanese patients receiving ICI therapy.

Methods

This retrospective study analyzed patients treated with ICIs at the University of Fukui Hospital between November 2015 and October 2018. Cardiac irAEs were defined according to the ESC guidelines.

Results

Among 73 patients, six (8%) developed cardiac irAEs, with no fatalities. Echocardiographic assessment before ICI initiation revealed that patients who later developed cardiac irAEs had significantly lower ejection fractions (EFs) (p < 0.05). Receiver operating characteristic analysis demonstrated that left ventricular end-systolic diameters (LVDs) (area under the curve: AUC = 0.660) and EFs (AUC = 0.797) had moderate predictive value for cardiac irAEs. Kaplan–Meier analysis showed a higher probability of cardiac irAEs in patients with LVDs and EFs beyond specific thresholds (p < 0.01). Poisson regression analysis indicated a decreasing risk of cardiac irAEs over time after ICI initiation.

Conclusion

Baseline echocardiographic parameters, particularly LVDs and EFs, can be useful predictors of cardiac irAEs in patients receiving ICI therapy. Early echocardiographic evaluation may facilitate risk stratification and improve monitoring strategies for cardiac irAEs.

Clinical trial registration number

UMIN000023840.